GlaxoSmithKline (GSK) appears to be focusing more on finding a new CEO than any large M&A deals after last year's $20 billion asset swap with Novartis, according to a briefing following strong Q1 ...

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in ...

Jeanne Whalen writes about the U.S. economy from the Chicago bureau. She previously covered healthcare, general news and ...

GSK CEO Emma Walmsley’s $13 million salary is predicated on picking the right people to steer cutting-edge drug development for the world’s most challenging diseases. During her eight years at ...

The Trump administration's apparent vaccine skepticism and proposed tariffs on Pharma could significantly impact GSK plc's vaccine division and its overall profitability, despite CEO Walmsley's ...